0RQE Stock Overview A biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Idorsia Historical stock prices Current Share Price CHF 0.77 52 Week High CHF 3.69 52 Week Low CHF 0.63 Beta 1.26 1 Month Change 5.82% 3 Month Change -35.41% 1 Year Change -43.86% 3 Year Change -96.37% 5 Year Change -97.54% Change since IPO -93.70%
Recent News & Updates
Idorsia's Once-Daily Tryvio (Aprocitentan) Is Now Available in the U.S., Advancing Treatment Options for Millions of Patients with Difficult-To-Control Hypertension Nov 16
New minor risk - Shareholder dilution Nov 01
Third quarter 2024 earnings released: CHF0.56 loss per share (vs CHF1.27 profit in 3Q 2023) Oct 31
Idorsia Ltd Provides Earnings Guidance for 2024 Oct 29
Investor sentiment deteriorates as stock falls 17% Oct 17
Investor sentiment deteriorates as stock falls 16% Sep 23 See more updates
Idorsia's Once-Daily Tryvio (Aprocitentan) Is Now Available in the U.S., Advancing Treatment Options for Millions of Patients with Difficult-To-Control Hypertension Nov 16
New minor risk - Shareholder dilution Nov 01
Third quarter 2024 earnings released: CHF0.56 loss per share (vs CHF1.27 profit in 3Q 2023) Oct 31
Idorsia Ltd Provides Earnings Guidance for 2024 Oct 29
Investor sentiment deteriorates as stock falls 17% Oct 17
Investor sentiment deteriorates as stock falls 16% Sep 23
Investor sentiment deteriorates as stock falls 15% Sep 03
Investor sentiment deteriorates as stock falls 21% Aug 02
Second quarter 2024 earnings released: CHF0.60 loss per share (vs CHF1.08 loss in 2Q 2023) Jul 26 Idorsia Ltd to Report Fiscal Year 2024 Results on Feb 27, 2025
Idorsia Ltd Receives Approval from the European Commission for JERAYGO™ Jul 01
Idorsia Ltd Approves Board Appointments Jun 15
New major risk - Revenue and earnings growth May 23
Full year 2023 earnings released: CHF1.67 loss per share (vs CHF4.67 loss in FY 2022) May 23
Idorsia Ltd to Report Nine Months, 2024 Results on Oct 29, 2024 May 22
New major risk - Share price stability Nov 06
Idorsia Ltd Announces New Phase 3 Data with Aprocitentan for Patients with Resistant Hypertension Presents At the American Society of Nephrology Kidney Week 2023 Nov 04
Third quarter 2023 earnings released: EPS: CHF1.26 (vs CHF1.22 loss in 3Q 2022) Oct 26
New major risk - Revenue and earnings growth Oct 25 Idorsia Ltd Updates Earnings Guidance for the Year 2023
New major risk - Financial position Jul 26
Second quarter 2023 earnings released: CHF1.08 loss per share (vs CHF1.25 loss in 2Q 2022) Jul 26 Idorsia Ltd to Report Q1, 2024 Results on Apr 25, 2024
Sosei Group Corporation (TSE:4565) entered into an agreement to acquire Idorsia Pharmaceuticals Japan Ltd/Idorsia Pharmaceuticals Korea Co., Ltd from Idorsia Ltd (SWX:IDIA) for JPY 65 billion. Jul 22
Idorsia Launches Quviviq (Daridorexant) in Switzerland – A First-In-Class Treatment for Chronic Insomnia Disorder to Improve Both Nighttime Symptoms and Daytime Functioning Jun 12
First quarter 2023 earnings released: CHF1.19 loss per share (vs CHF1.12 loss in 1Q 2022) Apr 27
Idorsia Ltd Provides Earnings Guidance for the Year 2023 Feb 08
Full year 2022 earnings released: CHF4.67 loss per share (vs CHF3.77 loss in FY 2021) Feb 08
No longer forecast to breakeven Feb 07
Idorsia Ltd Provides Earnings Guidance for the Year 2023 Feb 07
Idorsia Ltd to Report Q3, 2023 Results on Oct 24, 2023 Feb 05
Forecast to breakeven in 2025 Dec 31
Idorsia Ltd Submits New Drug Application to the US FDA for Aprocitentan for Treatment of Patients with Difficult-to-Control Hypertension Dec 20
Idorsia Ltd Announces Long-Term Safety and Tolerability Results with Daridorexant in Patients with Insomnia Disorder Published in CNS Drugs Dec 13
Idorsia Ltd Announces Swissmedic Approves QUVIVIQ (daridorexant) – A First-In-Class Treatment for Chronic Insomnia Disorder to Improve Both Nighttime Symptoms and Daytime Functioning Dec 05
No independent directors Nov 16
The Janssen Pharmaceutical Companies, in Collaboration with Idorsia Ltd, Announce Results from the Phase 3 Precision Study Nov 09
The Janssen Pharmaceutical Companies, in Collaboration with Idorsia Ltd, Announce Results from the Phase 3 Precision Study Nov 08
Third quarter 2022 earnings released: CHF1.22 loss per share (vs CHF0.83 loss in 3Q 2021) Oct 26 Idorsia Ltd Provides Earnings Guidance for the Year 2022
Now 21% undervalued after recent price drop Oct 05
Now 20% undervalued Sep 14
Second quarter 2022 earnings released: CHF1.25 loss per share (vs CHF0.83 loss in 2Q 2021) Jul 27
Idorsia Ltd to Report Q1, 2023 Results on Apr 25, 2023 Jul 26
Now 22% undervalued after recent price drop Jul 12
Idorsia Ltd Announces Positive Phase 3 Study with Aprocitentan Demonstrates Significant Antihypertensive Efficacy in Patients with Resistant Hypertension May 23 Idorsia Ltd Announces Phase 2A Study Results in Binge Eating Disorder May 10
Full year 2021 earnings released: CHF3.77 loss per share (vs CHF3.12 loss in FY 2020) Apr 27
No independent directors Apr 27
Idorsia Ltd to Report Fiscal Year 2022 Results on Feb 07, 2023 Apr 26
Idorsia Ltd and Idorsia Pharmaceuticals Japan Announces Availability of Pivlaz™ (Clazosentan) to Physicians in Japan to Start Treating Asah Patients Apr 20
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Feb 10 Idorsia Ltd Announces Revenue Guidance for Full Year 2022
Idorsia Receives US FDA Approval of QUVIVIQ (daridorexant) 25 and 50 mg for the Treatment of Adults with Insomnia Jan 10
Third quarter 2021 earnings released: CHF0.83 loss per share (vs CHF0.83 loss in 3Q 2020) Oct 29
Second quarter 2021 earnings released: CHF0.83 loss per share (vs CHF0.51 loss in 2Q 2020) Jul 31
Idorsia to Present New Phase 3 Data on Daridorexant in Insomnia at Sleep 2021 Jun 09
Director has left the company May 22
Director has left the company May 22
First quarter 2021 earnings released: CHF0.63 loss per share (vs CHF0.92 loss in 1Q 2020) Apr 24
Idorsia Ltd Announces US FDA Approves Ponvory (ponesimod) to Treat Adults with Relapsing Forms of Multiple Sclerosis Mar 21
FDA Accepts the New Drug Application for Review of Idorsia’s Daridorexant for the Treatment of Adult Patients with Insomnia Mar 11
Idorsia Ltd Announces Submission of New Drug Application to the Japanese Pharmaceuticals and Medical Devices Agency for Clazosenta Mar 01
New 90-day low: CHF24.55 Feb 23
Revenue misses expectations Feb 09
Full year 2020 earnings released: CHF3.12 loss per share (vs CHF3.76 loss in FY 2019) Feb 09
Idorsia Ltd to Report Q3, 2021 Results on Oct 26, 2021 Feb 04
New 90-day high: CHF28.05 Jan 19
New 90-day low: CHF21.16 Dec 07
New 90-day low: CHF21.16 Nov 20
New 90-day low: CHF21.16 Oct 30
Idorsia Ltd to Report First Half, 2021 Results on Jul 27, 2021 Oct 28
New 90-day low: CHF24.40 Oct 06
New 90-day low - CHF24.46 Sep 05
Idorsia Ltd to Report Q1, 2021 Results on Apr 22, 2021 Jul 23 Shareholder Returns 0RQE GB Biotechs GB Market 7D -4.6% -3.2% 1.6% 1Y -43.9% -24.1% 10.2%
See full shareholder returns
Return vs Industry: 0RQE underperformed the UK Biotechs industry which returned -23% over the past year.
Return vs Market: 0RQE underperformed the UK Market which returned 10% over the past year.
Price Volatility Is 0RQE's price volatile compared to industry and market? 0RQE volatility 0RQE Average Weekly Movement 24.7% Biotechs Industry Average Movement 8.9% Market Average Movement 4.9% 10% most volatile stocks in GB Market 11.3% 10% least volatile stocks in GB Market 2.7%
Stable Share Price: 0RQE's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0RQE's weekly volatility has increased from 17% to 25% over the past year.
About the Company Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant) for the treatment of adult patients with insomnia.
Show more Idorsia Ltd Fundamentals Summary How do Idorsia's earnings and revenue compare to its market cap? 0RQE fundamental statistics Market cap CHF 145.88m Earnings (TTM ) -CHF 296.43m Revenue (TTM ) CHF 74.12m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0RQE income statement (TTM ) Revenue CHF 74.12m Cost of Revenue CHF 186.54m Gross Profit -CHF 112.41m Other Expenses CHF 184.01m Earnings -CHF 296.43m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 27, 2025
Earnings per share (EPS) -1.57 Gross Margin -151.66% Net Profit Margin -399.92% Debt/Equity Ratio -100.5%
How did 0RQE perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/23 16:06 End of Day Share Price 2025/01/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Idorsia Ltd is covered by 13 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Maria Maldonado Bank Vontobel AG Jean-Philippe Bertschy Bank Vontobel AG Rosie Turner Barclays
Show 10 more analysts 
